Recent large-scale transcriptomic analyses have defined three robust subtypes of KRAS G12C-mutant NSCLC (KC, KL, and KP) with distinct gene expression signatures, co-mutation patterns, immune microenvironments, and clinical outcomes. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.